Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103314 | 0.90 | TAS2R14 (0.40) | OPRM1CTSLTAS2R14MEN1KMT2A | |
| SCHEMBL3100054 | 0.87 | CTSL (0.36) | OPRM1CTSLMEN1KMT2AKDM4E | |
| SCHEMBL3088478 | 0.86 | MMP8 (0.39) | MLYCDIDO1MEN1KMT2AKDM4E | |
| SCHEMBL3099793 | 0.86 | MEN1 (0.35) | CTSLMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3090474 | 0.85 | CTSL (0.35) | OPRM1AGTR2CTSL | |
| SCHEMBL3093486 | 0.84 | CTSL (0.34) | CTSL | |
| SCHEMBL3087951 | 0.82 | KMT2A (0.40) | OPRM1CTSLMEN1KMT2AALDH1A1 | |
| SCHEMBL3103766 | 0.82 | CTSL (0.35) | OPRM1AGTR2CTSLKMT2A | |
| SCHEMBL3097794 | 0.81 | BCL2L1 (0.41) | CTSLMEN1KMT2A | |
| SCHEMBL3100742 | 0.80 | MMP8 (0.41) | MLYCDKMT2AKDM4EALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-10-04 | — | — | US | claimed |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-09-11 | — | — | US | claimed |
| EP-3127554-A1 | MEDICINE FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | National Cerebral and Cardiovascular Center (JP) | 2017-02-08 | — | — | EP | claimed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | claimed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | claimed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | claimed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | claimed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | claimed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-09-11 | — | — | US | disclosed |
| EP-3127554-A1 | MEDICINE FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | National Cerebral and Cardiovascular Center (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-9291597-B2 | Detecting targets using mass tags and mass spectrometry | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | AGTR2, AGTR1, REN | OPRM1 655/4885MLYCD 4615/4885AGTR2 1/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | OPRM1 2431/4885MLYCD 342/4885AGTR2 2/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | OPRM1 483/4885MLYCD 764/4885AGTR2 1/4885 |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | AGTR2, MME, AGTR1 | OPRM1 483/4885MLYCD 764/4885AGTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.